Mortality risk of antipsychotic augmentation for adult depression

Mortality risk of antipsychotic augmentation for adult depression

Show other versions (1)

Importance Randomized controlled trials have demonstrated increased all-cause mortality in elderly patients with dementia treated with newer antipsychotics. It is unknown whether this risk generalizes to non-elderly adults using newer antipsychotics as augmentation treatment for depression. Objectiv...

Full description

Bibliographic Details
Main Authors:	Tobias Gerhard, T. Scott Stroup, Christoph U. Correll, Soko Setoguchi, Brian L. Strom, Cecilia Huang, Zhiqiang Tan, Stephen Crystal, Mark Olfson, James M. Wright
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526884/?tool=EBI

Similar Items

Mortality risk of antipsychotic augmentation for adult depression.
by: Tobias Gerhard, et al.
Published: (2020-01-01)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01)

Body mass index and all-cause mortality in a 21st century U.S. population: A National Health Interview Survey analysis.
by: Aayush Visaria, et al.
Published: (2023-01-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
by: Correll Christoph U, et al.
Published: (2008-04-01)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
by: Alexandria S. Coles, et al.
Published: (2021-12-01)

Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents
by: Bettina Frank, et al.
Published: (2023-09-01)

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs
by: Julia M Gohlke, et al.
Published: (2012-06-01)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
by: X.J. Wen, et al.
Published: (2014-07-01)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
by: Fredrik Hieronymus, et al.
Published: (2021-08-01)

Atypical antipsychotics as augmentation therapy in anorexia nervosa.
by: Enrica Marzola, et al.
Published: (2015-01-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
by: Jimmy Gonzalez, et al.
Published: (2023-03-01)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
by: Koen Demyttenaere, et al.
Published: (2022-04-01)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
by: Christoph U. Correll, et al.
Published: (2022-02-01)

Antipsychotics and Mortality in Adult and Geriatric Patients with Schizophrenia
by: Ling-Ling Yeh, et al.
Published: (2023-12-01)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
by: Jolanta Orzelska-Górka, et al.
Published: (2022-09-01)

The effects of antipsychotic drugs on depression level in patients with schizophrenia: clozapine vs. other atypical antipsychotics
by: Hülya Ertekin, et al.
Published: (2016-08-01)

Evaluation of naltrexone augmentation to the antipsychotic drugs on positive and negative symptoms of schizophrenia
by: Javad Setareh, et al.
Published: (2008-01-01)

Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia
by: Zachary Boivin, et al.
Published: (2019-11-01)

Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series
by: Enrico Pessina, et al.
Published: (2023-11-01)

Atypical antipsychotics as add-on treatment in late-life depression
by: Cakir S, et al.
Published: (2016-09-01)

Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications
by: Anuradha Baminiwatta, et al.
Published: (2023-06-01)

Racial differences in setting of implantable cardioverter-defibrillator placement in older adults with heart failure and association with disparate post-implant outcomes
by: Ehimare Akhabue, et al.
Published: (2023-09-01)

Associated mortality risk of atypical antipsychotic medication in individuals with dementia
by: Phiri, P, et al.
Published: (2022)

Trends in cardiac rehabilitation rates among patients admitted for acute heart failure in Japan, 2009–2020
by: Junghyun Kim, et al.
Published: (2023-01-01)

A case of postpsychotic depression improved by switching antipsychotic monotherapy
by: Yoshiyo Oguchi, et al.
Published: (2023-03-01)

Does augmentation with antipsychotic agents affect the medication adherence of the child with obsessive-compulsive disorder?
by: Tayfun Kara, et al.
Published: (2019-03-01)

Comparing record linkage software programs and algorithms using real-world data.
by: Alan F Karr, et al.
Published: (2019-01-01)

antipsychotics and metabolic syndrome
by: R. Jomli, et al.
Published: (2022-06-01)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
by: Celso Arango, et al.
Published: (2023-06-01)

Psychological and Psychopharmacological Interventions in Psychocardiology
by: Kai G. Kahl, et al.
Published: (2022-03-01)

Melatonin as a pathway to decrease mortality rates associated with antipsychotic therapy.
by: Dmytro Krupka, et al.
Published: (2023-10-01)

Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
by: Amber N. Edinoff, et al.
Published: (2022-03-01)

Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data
by: Rashmi Patel, et al.
Published: (2023-11-01)

Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study.
by: Alex J Mitchell, et al.
Published: (2019-01-01)

Hypocalcemia may be associated with extensive Fournier’s gangrene and mortality
by: G. Soko, et al.
Published: (2020-07-01)

Atypical antipsychotics, more than just an antipsychotic
by: Hiram Tendilla-Beltran, et al.
Published: (2020-01-01)

Gender Differences in the Association Between Screen Time and Depression
by: Lauren E. Kleidermacher, MSc, et al.
Published: (2024-04-01)

27 Racial-Ethnic Differences in Antipsychotic Initiation Among Youth with Diagnosed ADHD, Depression, or Conduct Disorder
by: Linnea Sepe-Forrest, et al.
Published: (2024-04-01)

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
by: Christoph U. Correll, et al.
Published: (2022-01-01)